Clinical applications of radio-frequency ablation in liver metastasis of colorectal cancer

Ji Hun Gwak, Bo Young Oh, Ryung Ah Lee, Soon Sup Chung, Kwang Ho Kim

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Purpose: The aim of this study is to evaluate long-term survival and prognostic factors for radio-frequency ablation (RFA) in colorectal liver metastases. Methods: We retrospectively reviewed 35 colorectal liver metastases patients who underwent RFA between 2004 and 2008. We analyzed survival after RFA and prognostic factors for survival. Results: Of the 35 patients, 23 patients were male and 12 were female. Their mean age was 62.40 ± 12.52 years. Mean overall survival was 38.8 ± 4.6 months, and mean progression free survival was 19.9 ± 3.4 months. Three- and 5-year overall survival rates were 42.7 ± 0.1% and 26.0 ± 0.1%, respectively. Three- and 5-year progression-free survival rates were 19.6 ± 0.1% and 4.9 ± 0.04%, respectively. Overall survival and progression-free survival were significantly improved in male and in patients with carcinoembryonic antigen (CEA) ≤ 100 ng/mL, carbohydrate antigen (CA) 19-9 ≤ 100 ng/mL, absence of extrahepatic disease, and a unilobar hepatic lesion. In addition, progression-free survival was improved in patients with a solitary hepatic lesion. On the multivariate analysis, significant survival factors were the absence of extrahepatic disease and the presence of a unilobar hepatic lesion. Conclusion: RFA for colorectal liver metastases is an effective treatment option in male patients and in patients with CEA or CA19-9 ≤ 100, absence of extrahepatic disease, a solitary hepatic lesion, and a unilobar hepatic lesion.

Original languageEnglish
Pages (from-to)202-210
Number of pages9
JournalJournal of the Korean Society of Coloproctology
Issue number4
StatePublished - 31 Aug 2011


  • Colorectal liver matastasis
  • Prognostic factor
  • Radiofrequency ablation
  • Survival


Dive into the research topics of 'Clinical applications of radio-frequency ablation in liver metastasis of colorectal cancer'. Together they form a unique fingerprint.

Cite this